New artistic director shakes things up at Marin Shakes
Change is afoot at Marin Shakespeare Company. And a big catalyst of that change is the introduction of a new artistic director, Jon Tracy.
Stay updated with breaking news from Open Access. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Change is afoot at Marin Shakespeare Company. And a big catalyst of that change is the introduction of a new artistic director, Jon Tracy.
Objectives To evaluate whether a multimodal intervention in general practice reduces the proportion of second line antibiotic prescriptions and the overall proportion of antibiotic prescriptions for uncomplicated urinary tract infections in women. Design Parallel, cluster randomised, controlled trial. Setting General practices in five regions in Germany. Data were collected between 1 April 2021 and 31 March 2022. Participants General practitioners from 128 randomly assigned practices. Interventions Multimodal intervention consisting of guideline recommendations for general practitioners and pa...
These two new Open Access journals bring together expert multidisciplinary research to influence a broad audience of stakeholders.
News SiFi Networks, the company behind the build, said the fiber network will be completed at no cost or risk to taxpayers, according to a statement from the company. More than 50,000 residents, businesses, and institutions will be connected to high-speed internet when a new $70 million privately-funded open access network project is completed in…
Objective To assess the efficacy and safety of pyrotinib (an irreversible pan-HER (human epidermal growth factor receptor) inhibitor), trastuzumab, and docetaxel compared with placebo, trastuzumab, and docetaxel for untreated HER2 positive metastatic breast cancer. Design Randomised, double blind, placebo controlled, multicentre, phase 3 trial. Setting 40 centres in China between 6 May 2019 and 17 January 2022. Participants 590 female patients (median age 52 (interquartile range 46-58) years) with untreated HER2 positive metastatic breast cancer. Interventions Eligible patients were randomised...